LIXT Insider Trading

Lixte Biotechnology Holdings, Inc. (LIXT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $89.1M, listed on NASDAQ, employing roughly 3 people, carrying a beta of 1.25 to the broader market. Lixte Biotechnology Holdings, Inc. Led by Geordan G. Pursglove, public since 2007-10-25.

In the last 12 months, Lixte Biotechnology Holdings, Inc. insiders made 0 buy transactions and 0 sale transactions.

DateNameTypeSharesPriceValue
Jul 2, 2026Stazzone PeterA-Award50,000$0.00$0
Jul 2, 2026Sawyer Jason DavidA-Award40,000$0.00$0
Jul 2, 2026Pursglove Geordan GarrettA-Award350,000$0.00$0
Jul 2, 2026Primus Guy WarrenA-Award15,000$0.00$0
Jul 2, 2026Holloway Michael AndrewA-Award15,000$0.00$0
Jul 2, 2026Felix LourdesA-Award30,000$0.00$0
Jul 2, 2026Travaglini John Francis0$0.00$0
Jun 1, 2026Porter Stuart DA-Award25,000$0.00$0
Jun 1, 2026Porter Stuart D0$0.00$0
Apr 17, 2026Pursglove Geordan GarrettA-Award350,000$0.00$0

How to Read LIXT Insider Activity

Net insider activity is balanced over the trailing twelve months: 0 buys against 0 sales. Balanced activity typically reflects routine compensation-related vesting and tax-driven liquidity rather than directional information signals. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →